Your browser doesn't support javascript.
loading
MET alterations as resistance mechanisms of dabrafenib-trametinib in BRAF p.V600E mutated non-small cell lung cancer patient.
Pluchino, Monica; Testi, Irene; Minari, Roberta; Dodi, Alessandra; Airò, Giulia; Mazzaschi, Giulia; Verzè, Michela; Adorni, Alessia; Gnetti, Letizia; Azzoni, Cinzia; Lagrasta, Costanza Anna Maria; Pecci, Federica; Tiseo, Marcello.
Afiliação
  • Pluchino M; Oncology and Hematology Department, Medical Oncology Unit, University Hospital of Parma.
  • Testi I; Department of Medicine and Surgery, University of Parma, Parma.
  • Minari R; Oncology and Hematology Department, Medical Oncology Unit, University Hospital of Parma.
  • Dodi A; Department of Medicine and Surgery, University of Parma, Parma.
  • Airò G; Oncology and Hematology Department, Medical Oncology Unit, University Hospital of Parma.
  • Mazzaschi G; Oncology and Hematology Department, Medical Oncology Unit, University Hospital of Parma.
  • Verzè M; Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona.
  • Adorni A; Oncology and Hematology Department, Medical Oncology Unit, University Hospital of Parma.
  • Gnetti L; Department of Medicine and Surgery, University of Parma, Parma.
  • Azzoni C; Oncology and Hematology Department, Medical Oncology Unit, University Hospital of Parma.
  • Lagrasta CAM; Department of Medicine and Surgery, University of Parma, Parma.
  • Pecci F; Oncology and Hematology Department, Medical Oncology Unit, University Hospital of Parma.
  • Tiseo M; Department of Medicine and Surgery, University of Parma, Parma.
Anticancer Drugs ; 35(8): 761-763, 2024 Sep 01.
Article em En | MEDLINE | ID: mdl-39115059
ABSTRACT
The combination of BRAF and MEK inhibitors demonstrated significant clinical benefit in patients with BRAF-mutant non-small cell lung cancer (NSCLC). However, the molecular mechanisms of acquired resistance to BRAF and MEK inhibition in NSCLC are still unknown. Herein, we report a case of a 76-year-old man with a history of smoking who was diagnosed with BRAF V600E-mutant lung adenocarcinoma (PD-L1 > 50%) and subsequently candidate to first-line therapy with pembrolizumab. After 18 months since the start of immunotherapy, computed tomography scan showed disease progression and a second-line therapy with dabrafenib and trametinib was initiated. Seven months later, due to a suspect disease progression, a left supraclavicular lymphadenectomy was performed and next-generation sequencing analysis revealed the appearance of MET exon 14 skipping mutation, while fluorescence in situ hybridization analysis showed MET amplification. The patient is still on BRAF and MEK inhibitor treatment. Our case highlights the relevance of performing tumor tissue rebiopsy at the time of progression during treatment with BRAF/MEK inhibition with the aim of identifying putative mechanisms of resistance.
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oximas / Piridonas / Pirimidinonas / Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma Pulmonar de Células não Pequenas / Resistencia a Medicamentos Antineoplásicos / Proteínas Proto-Oncogênicas c-met / Proteínas Proto-Oncogênicas B-raf / Imidazóis / Neoplasias Pulmonares Limite: Aged / Humans / Male Idioma: En Revista: Anticancer Drugs Assunto da revista: ANTINEOPLASICOS Ano de publicação: 2024 Tipo de documento: Article País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oximas / Piridonas / Pirimidinonas / Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma Pulmonar de Células não Pequenas / Resistencia a Medicamentos Antineoplásicos / Proteínas Proto-Oncogênicas c-met / Proteínas Proto-Oncogênicas B-raf / Imidazóis / Neoplasias Pulmonares Limite: Aged / Humans / Male Idioma: En Revista: Anticancer Drugs Assunto da revista: ANTINEOPLASICOS Ano de publicação: 2024 Tipo de documento: Article País de publicação: Reino Unido